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Role of Prostaglandin-H Synthase in
Mediating Genotoxic and Carcinogenic
Effects of Estrogens
by Gisela H. Degen*
Diethylstilbestrol (DES) has been found to be oxidized in Syrian hamster embryo (SHE) cells by pros-
taglandin-H synthase (PGH synthase). It is hypothesized that PGH synthase mediates adverse effects of
DES and other carcinogenic estrogens such as induction of neoplastic transformation and genotoxicity.
Interest in PGH synthase-catalyzed reactions focuses on two aspects: oxidation and metabolic activation
of stilbene and steroid estrogens by PGH synthase, and modulation of prostaglandin biosynthesis via
effects ofthese compounds on PGH synthase. Studies of the former aspect ofPGH synthase-catalyzed in
vitro metabolism have revealed that cooxidation ofDES, DES analogues, and steroid estrogens gives rise
to reactive intermediates; DES and DES analogues known to transform SHE cells are metabolized by
PGH synthase in vitro; PGH synthase catalyzes both the formation and oxidation ofcatechol metabolites
from steroid estrogens, and reactive intermediates from DES and from steroid estrogens are stable enough
to bind both to the catalytic enzyme PGH synthase and to other proteins. The data support the contention
that PGH synthase-catalyzed metabolic activation plays a role in the induction of neoplastic transfor-
mation by stilbene and steroid estrogens but is not conclusive evidence for a cause-effect relationship.
More recently, two closely related DES indanyl analogues have been found to differ in their interaction
with PGH synthase: indenestrol A is cooxidized and activated like DES, whereas indenestrol B inhibits
the enzyme. They provide useful tools to test the above hypothesis from a new perspective. The interaction
between estrogens and PGH synthase is also viewed with respect to its potential role in tumor promotion
and progression, processes in which prostaglandins have been implicated as important mediators. Coox-
idation of estrogens in vitro is accompanied by a stoichiometric increase in prostaglandin production.
Useful approaches to study this and other effects of estrogens on PGH synthase that could result in a
modulation of prostaglandin biosynthesis are discussed.
Introduction
Estrogens with documented carcinogenic activity in
vivo can neoplastically transform cells in culture and
induce genotoxicity in some in vitro systems (1). Di-
ethylstilbestrol (DES), several DES analogues, and
steroid estrogens have been found to induce neoplastic
transformation of Syrian hamster embryo fibroblasts
(SHE cells) (2,3) and ofBalb/c 3T3 cells (4). For a num-
ber ofthese compounds, the neoplastic activity in vitro
or in vivo, e.g., in the hamster kidney tumor model,
did not correlate with hormonal activity, suggesting
that their estrogenicity is not the whole explanation of
their carcinogenic properties. Metabolic activation has
been proposed to play an important role in the mech-
anism of action of DES and of steroid estrogens (5-7)
butwhetheritisrequiredis still anunresolvedquestion.
In SHE cells, DES is metabolized by prostaglandin-
H synthase (PGH synthase), an enzyme also present in
other target cells (8). Furthermore, induction of sister
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chromatid exchange by DES in certain cells is inhibited
by indomethacin (9,10), a well-known PGH synthase
inhibitor. These observations stimulated our interest in
the PGH synthase-catalyzed oxidation of carcinogenic
estrogens and its possible role in the process of neo-
plastic transformation induced by these compounds.
PGH synthase, a key enzyme in the biosynthesis of
prostaglandins (PG) has both cyclooxygenase and per-
oxidase activity and catalyzes the oxygenation of ar-
achidonic acid to the hydroperoxy endoperoxide PGG2
and its reduction to the hydroxy endoperoxide PGH2.
The peroxidase reaction is accompanied by oxidation of
(reducing) co-substrates (cooxidation). The PGH syn-
thase-mediated in vitro oxidation of many xenobiotics
yields electron-deficient, reactive intermediates, and
techniques have been developed to estimate its in vivo
contribution to the metabolic activation ofchemical car-
cinogens (11). We have studied the oxidation of DES
and its structural analogues as well as the PGH syn-
thase-catalyzed metabolism of steroid estrogens and
their catechol metabolites.
It is also of interest to establish whether the inter-G. H. DEGEN
action between PGH synthase and estrogens could re-
sult inamodulation ofprostaglandin biosynthesis. Pros-
taglandins (in particular PGE2) have been implicated as
important mediators in tumor promotion and progres-
sion (12). That PGH synthase and its products may well
play a role in hormonal carcinogenesis is suggested by
observations that many tumors in estrogen target tis-
sues progress under the influence of unsaturated pre-
cursor (X-6) fatty acids, that murine mammary tumor
growth can be inhibited by indomethacin (13-15), and
thathumanbreastepithelialcellsproliferateinresponse
to PGE2 (16). Cyclic variations in PGbiosynthesis occur
in estrogen target tissues (17,18) so that a better un-
derstanding of the regulation and inducibility of PGH
synthase by sex hormones seems to promise new in-
sights in this field.
Methods
PGH Synthase-Catalyzed Metabolism of
DES and Related Compounds
DES, DES analogues (Fig. 1), and steroid estrogens
were incubated with microsomal or purified PGH syn-
thase preparations in the presence of arachidonic acid
(ARA) or peroxides (15-HPETE or H202); the conver-
sion of estrogen parent compounds and the formation
of products was assessed by HPLC analysis of incu-
bation extracts as previously described in detail (19-
21). Aryl hydroxylation ofestrogens was determined in
incubations withregiospecifically tritiatedestradiol (E2)
or DES by the tritiumwaterrelease assay and by prod-
uct identification (21,22).
Protein Binding of Reactive Estrogen
Intermediates
Nonextractable binding to microsomal protein was
found upon oxidation ofradiolabeled estrogens by PGH
synthase (23). The nature of the protein binding has
been further studied in a refined in vitro system: es-
trogens, radiolabeled in a metabolically stable position,
were activated by purified PGH synthase in the pres-
ence of various amounts of albumin (BSA) and/or tub-
ulin. The amounts of radioactivity covalently bound to
individual proteinswere determined afterSDS-gelelec-
trophoresis by autoradiography and by combustion of
excised gel bands followed by liquid scintillation count-
ing (LSC) (21).
Effects of Estrogens on Prostaglandin
Synthesis In Vitro
PGE2 synthesis from radiolabeled arachidonic acid
was measured in PGH synthase incubations inthe pres-
ence ofepinephrine (as reducing co-substrate) and var-
ious concentrations of DES indanyl analogues or indo-
methacin (Fig. 2). Inhibitory or stimulatory effects on
arachidonic acid metabolismwere also studied usingthe
cyclooxygenase assay (20,24).
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FIGURE 1. Structures of DES and related compounds.
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FIGURE 2. PGE2-synthesis invitrointhe presence oftestcompoundsindenestrolA, indenestrol B, orindomethacin. MicrosomalPGH synthase
(0.12 mg RSVM protein in 2.0 mL phosphate buffer, 0.05 M, pH 7.5, 1.0 mM epinephrine, and 0.5 mM GSH) was incubated with 14C-
arachidonic acid (100 ,uM) and the indicated concentrations oftest compounds for5 min at37°C. PGE2 synthesis was determined inincubation
extracts by radio-TLC as previously described (28). Dotted lines indicate the range of PGE2 synthesis in controls with epinephrine (1.0
mM) and GSH (0.5 mM) but without addition of test compounds.
Results and Discussion
Metabolism of DES and DES Analogues by
PGH Synthase
PGH synthase oxidizes DES in vitro by means ofits
peroxidase activity, predominantly to Z,Z-dienestrol
(Z,Z-DIES), a metabolite also formed from catalysis
with other peroxidases (5,19,25). The closely related
derivatives, TF-DES and DMS (Fig. 1) are also oxidized
via para-quinoid intermediates to the corresponding
dien products (26).
Other DES analogues without the conjugated double
bond but with free phenolic groups (e.g., HES; E,E-
DIES) are metabolized by PGH synthase via one-elec-
tronoxidation, primarilytophenoxyradicals (20). Coox-
idation of DES and related compounds is accompanied
by the formation of protein-bound products indicative
of reactive (quinone or radical) intermediates. This
makes PGH synthase a candidate enzyme for the met-
abolic activation of stilbene estrogens. DES oxidation
by PGH synthase has been demonstrated in SHE cells
(8). It is unknown to what extent estrogens are cooxi-
dized in vivo in target tissues known to contain PGH
synthase, e.g., uterus and breast. Taken together, our
data show that DES and several DES analogues are
metabolized and activated by PGH synthase, and a cor-
relation between in vitro conversion of the compounds
andtheirtransformingactivityinSHE cellsisobserved.
PGH Synthase-Mediated Oxidation of
Steroid Estrogens
Since several steroid estrogens and theircatechol me-
tabolites are known to transform cells in culture (3,27),
their PGH synthase-catalyzed metabolism has been
studied too. Estradiol (E2), ethinyl-E2, estrone (E1),
and estriol are metabolized by ARA-supplemented mi-
crosomal PGH synthase to a similar extent, and this is
accompanied by the formation of protein-bound prod-
ucts; the catechols (e.g., 2-OH-E2 and 2-OH-E1) are
oxidized more extensively than monophenolic estrogens
(23). PGH synthase oxidizes by stepwise, one-electron
abstraction: monophenolic estrogens are oxidized to
phenoxy radicals, catechols to semiquinones and qui-
nones; spectral detection ofthe (reactive) ortho-quinone
intermediate is facilitated in incubations of 2-OH-E2
with minute amounts of purified, highly active enzyme
protein (28). Interestingly, PGH synthasealsocatalyzes
the formation of catechols from steroid estrogens, as
shown by tritium release from C-2 and C-4 (Table 1)
and confirmed by product identification. The proposed
mechanism is shown in Figure 3.
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Table 1. PGH synthase-catalyzed regiospecific 3H2O release from estradiol and DES.
Radioactivity released as 3H20, % label, in
Structure and position of 3H label Complete incubationsa Controlsb
E2 OH 42.3 ± 2.3 2.7 ± 0.1
T
HO
E2 OH 29.0 ± 2.8 3.4 ± 0.1
K~~~~
HO
DES 6.5 ± 0.1 0.4 ± 0.0
T
HO/-T
- ~~~~OH
T
T
aTritiated estrogens (10 and 50 ,uM) were incubated for 5 min at 37°C with microsomal PGH synthase (0.5 mg) and arachidonic acid (100
nhM). b'Incubations with heat inactivated protein (21,22).
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The formation of catechols from steroid estrogens is
novel evidence for PGH synthase-mediated aryl hy-
droxylation: for suitable co-substrates such as E2 it is
a major reaction; for DES, which is oxidized mostly to
Z,Z-DIES, it plays a minor role in vitro as has been
studied using regiospecific tritium release from ortho-
tritiated analogues (Table 1). Thus, PGH synthase can
activate both stilbene and steroid estrogens via semi-
quinone and quinone intermediates (para- for stilbenes,
ortho- for steroids) (30).
Protein Binding of Reactive Estrogen
Intermediates Generated by PGH Synthase
Cooxidation
Binding to Usingan in vitro system with purified PGH synthase
Proteins and BSA as a competing nucleophile, we have recently shown that reactive intermediates of DES, HES, and
steroid estrogens are released from the catalytic en-
dlyzedformationandox- zyme and bind to other protein(s) in addition to PGH
ation ofestradiol yields synthase (21). Whether covalent modification of PGH
form); this reacts with synthase by estrogens in intact cells has biological im- rhich is (non-)enzymati- plications is unknown at present. Proteins ofthe spindle
ol that tautomerizes to . . .
[20 from orho-tritiated apparatus have been suggested as critical cellular tar-
tion proceeds via semi- gets (26). When tubulin is included in incubations with
PGH synthase, thereactive intermediates generated by
OJ!'I
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Table 2. PGH synthase cooxidation generates reactives intermediates of DES and estrone that bind preferentially to tubulin.
Radioactivity of estrogen bound to separated protein bands, dpm
Incubationa Ab BC PGH synthase BSA Tubulin
E1, 5 jM, - ARA
PGH synthase-tubulin (1:1) 92 ± 35 107 ± 67 103 ± 30 NDd 412 ± 54
E1, 5 ,M, + ARA
PGH synthase-tubulin (1:1) 3808 ± 186 733 ± 130 1168 ± 55 ND 7970 ± 340
DES, 5 ,uM, - ARA
PGH synthase-tubulin (1:1) 81 ± 41 44 ± 21 182 ± 47 ND 2158 ± 293
DES, 5 ,uM, + ARA
PGH synthase-tubulin (1:1) 10120 ± 2260 1531 ± 204 2377 ± 421 ND 6842 ± 580
DES, 5 ,uM, + ARA
PGH synthase-tubulin (1:4) 15172 ± 1335 2070 ± 435 2069 ± 108 ND 25925 ± 2100
DES, 5 ,uM, + ARA
PGH synthase-BSA-tubulin (1:1:1) 10801 ± 1876 1357 ± 614 2294 ± 335 1961 ± 418 8649 ± 186
DES, 5 ,uM, + ARA
PGH synthase-BSA-tubulin (1:4:1) 11198 ± 1112 2058 ± 1195 3573 ± 1417 6886 ± 1203 8779 ± 1705
aIncubations contained radiolabeled E1 (121, 334 dpm/nmole) or DES (133,200 dpm/nmole) with or without arachidonic acid (ARA 50 ,uM), PGH
synthase (15 jig/mL), and the other proteins in the ratios indicated.
bA, sample load (crosslinked proteins).
cB, region ofmicrotubule-associated proteins.
dND, not determined.
Table 3. Correlation between biological effects of several DES
structural analogues and their PGH synthase-catalyzed
metabolism in vitro.
PGH synthase
Compound Estrogenicity' Transformationb metabolismc
DES High + + + +
TF-DES Medium + + + +
DMS Low +d + + +
HES High +e + +
Z,Z-DIES None + + +
E,E-DIES High +d + +
M-DES Very low +f +
DM-DES Very low --
IA Medium ? + + +
IB Medium ? Inhibits
aPotency in vivo according to literature data (30,37,38).
bSHE cell transformation data from McLachlan et al. (2) unless
otherwise indicated.
'Data from Degen et al. (20,24). See text for further details.
dResults not clearly positive when initially tested but clearly pos-
itive on reexamination (D. Schiffmann, personal communication).
'Results not clearly positive when initially tested but clearly pos-
itive on reexamination (T. Tsutsui, personal communication).
fResults not clearly positive when initially tested but clearly pos-
itive on reexamination (A. Wong, personal communication).
gNot significantly different from untreated controls.
cooxidation ofeitherradiolabeled DES orofestrone (E1)
bind preferentially to this protein, even in the presence
of excess BSA (Table 2). The reactive intermediates
also cause crosslinking ofproteins and modify PGH syn-
thase and microtubule-associated proteins covalently.
It has previously been shown that quinone interme-
diates of DES and 2-OH-E2 (but not E2) generated by
oxidation with horseradish peroxidase (HRP) react
preferentially with tubulin when proteins are added
afterafewminutesofincubationtime(29). Thenegative
results with E2 in the HRP system could be explained
either by short-lived intermediates or by an inability of
HRP to catalyze aryl hydroxylation to an extent similar
to PGH synthase, which would yield less catechol pre-
cursor for subsequent activation.
Taken together, our data support the view that PGH
synthase can provide (complete) metabolic activation of
stilbene and steroid estrogens, even in the absence of
monooxygenases that catalyze catechol formation. If
tubulin is a critical target molecule (26,29) for reactive
estrogen intermediates, these results support the con-
tention that PGH synthase mediates the induction of
aneuploidy by DES, DES-related compounds, and ster-
oid estrogens, an effect that could be involved in neo-
plastic transformation.
Structure-Activity Relationships
At present, there is no conclusive evidence that PGH
synthase-catalyzed metabolic activation is a decisive
factor in the mechanism ofaction ofcarcinogenic estro-
gens. However, thisproposalis supportedby structure-
activity relationships observed for a series of DES-
related compounds. The structures, together with in-
formation on their metabolism by PGH synthase as well
as transforming and estrogenic activity, are shown in
Table 3. Apparently, there is a correlation between the
ability to induce neoplastic transformation ofSHE cells
and in vitro PGH synthase-catalyzed metabolism: all
derivatives found to transform SHE cells (irrespective
of their estrogenicity) are also oxidized by PGH syn-
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thase in vitro except for the dimethyl ether of DES
(DM-DES), which is not metabolized.
Recently, closelyrelatedDESindanylanalogueshave
been found to differ in their interaction with PGH syn-
thase: indenestrol A (IA) is cooxidized and activated
like DES, whereas indenestrol B (IB) inhibits the en-
zyme (24). It is known that IA, an in vivo metabolite
of DES and IB, its synthetic isomer, have very similar
conformation and estrogenicity (30). IA is oxidized by
PGH synthase (orHRP) toapara-quinone intermediate
(20) that reacts with tubulin and inhibits its polymeri-
zation (26). In IB, one phenolic group is in the meta-
position relative to the central double bond, precluding
para-quinone formation. IB can be oxidized by perox-
idases, most likely to a phenoxy radical, but it is not
metabolized in a typical cooxidation reaction with ar-
achidonic acid-supplemented PGH synthase because it
inhibits the cyclooxygenase (24).
The different properties of these DES-indanyl ana-
logues should facilitate future studies concerning the
role of PGH synthase-mediated metabolism and of re-
active intermediates in their genotoxic action. Thus, it
is suggested that these compounds be included in stud-
ies assessing clastogenic and neoplastic potential.
Effects of Estrogenic Compounds on
Prostaglandin Biosynthesis
The different interaction ofIA and IB with PGH syn-
thase, as indicated by concentration-dependent stimu-
lation and inhibition of PGH synthase-cyclooxygenase
activity, respectively (24), isalsoreflected intheireffect
onPGE2 synthesis invitro. IA (10 ,uM) stimulatesPGE2
synthesis almost 3-fold above the control range (Fig. 2).
The slight inhibitory effect seen at the highest concen-
tration of IA is attributed to its antioxidant properties.
This has also been observed with other compounds that
are cooxidized; the compounds stimulate ARA conver-
sion at low concentrations, but inhibit conversion at
higher concentrations (20).
On the other hand, PGE2 synthesis is inhibited by IB
(Fig. 2). The IC50 is not different when it is determined
in the cyclooxygenase assay. IB inhibits with a similar
IC50, independent ofthe arachidonic acid concentration
and apparently not by an antioxidant type but an in-
domethacinlike type of inhibition (24).
In this context, it is of interest that some antiestro-
gens, e.g., tamoxifen and related compounds, inhibit
PGH synthase in vitro (31). Cooxidation of monophen-
olic or diphenolic estrogens, however, has been found
toresult in astimulation ofprostanoid synthesis invitro
(28). Their mode ofinteraction with PGH synthase and
the ability ofthe enzyme torecognize apparently rather
subtle structural differences of DES indanyl isomers is
an interesting facet ofthis problem. It is hoped that X-
ray structure analysis of the enzyme (32) will provide
additional clues tothe structural features involved. This
applies also for other compounds that exhibit marked
stereoselectivity as cyclooxygenase inhibitors but no
stereoselectivity as peroxidase-reducing substrates
(33).
PGH synthase-catalyzed oxidationofestrogenco-sub-
strates results in a nearly stoichiometric increase in
prostanoid synthesis in vitro (28). Therefore, although
estrogens can reach relatively high concentrations in
target tissues, cooxidation seems unlikely to affect PG
biosynthesis in vivo significantly unless estrogens in-
duce arachidonic acid release and/or PGH synthase ac-
tivity. Due to the complexity of the arachidonic acid
cascade (11), we prefer to focus on effects ofestrogens
on PGH synthase itselfthat could result in amodulation
of PG biosynthesis in vivo.
Future Perspectives
The production ofPGs has been suggested as a prog-
nostic marker for breast cancer patients (34) and is ap-
parently related, not only to changes in fatty acid
composition and availability, but also to increases in
PGH synthase activity as determined in biopsy homog-
enates in the presence of nonlimiting amounts of sub-
strate (35). Despite the well-known cyclic variations in
PG biosynthesis in estrogen target tissues (17,18), very
little is known as yet about the regulation and induci-
bility of PGH synthase by sex hormones. To develop
this latter aspect further, polyclonal antibodies against
highly purified ovine PGH synthase have been raised
for immunoblot analysis. The method presently used
detects 10 ng enzyme and has been applied successfully
to quantitate differences in PGH synthase levels in hu-
man (HL-60) cellsand inramseminal vesicles ofvarying
enzyme activity (36). Although further refinements are
required before the hormonal regulation of PGH syn-
thase in estrogen target tissues can be studied, the
cross-reactivity of the PGH synthase antiserum with
human PGH synthase (36) suggests that this approach
could also be applied to the study of PGH synthase
expression in human biopsy specimens.
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